Immunicum

About:

Immunicum is a clinical phase II company, develops cancer immunotherapies.

Twitter/X: immunicum

Description:

Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology.

Total Funding Amount:

$54.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Gothenburg, Vastra Gotaland, Sweden

Founded Date:

2002-01-01

Contact Email:

info(AT)immunicum.com

Founders:

Alex Karlsson- Parra

Number of Employees:

11-50

Last Funding Date:

2018-10-17

IPO Status:

Public

Industries: